Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.
Chamberlain
Marc C
MC
Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-0804, USA. ChambeMC@moffitt.usf.edu
Glantz
Michael J
MJ
Chalmers
Lisa
L
Van Horn
Alixis
A
Sloan
Andrew E
AE
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D011838:Radiation-Sensitizing Agents; D003606:Dacarbazine; D000077204:Temozolomide